Setara Biosciences branding accompanying the announcement of its $90 million Series A financing for precision medicine and rare disease drug development.
San Diego-based Setara Biosciences has secured $90 million in Series A financing from healthcare investors to advance its lead TRPV4 inhibitor, STAR-0871, and other genetics-based drug discovery programmes following its formation from Actio Biosciences.

Setara Biosciences, a San Diego, California-based clinical-stage biotechnology company developing precision medicines for genetic diseases, announced the completion of a $90 million Series A financing on October 30, 2026.

The funding round included participation from existing investors Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital and Regeneron Ventures. Jazz Pharmaceuticals also became a shareholder as part of its acquisition of Actio Biosciences.

Founded in 2026, Setara Biosciences was established following Jazz Pharmaceuticals’ acquisition of Actio Biosciences and its lead investigational treatment, ABS-1230, for KCNT1-related epilepsy. The new company was formed to continue developing Actio’s remaining drug discovery and clinical programmes.

Setara was co-founded by David Goldstein, who serves as president and executive chair, and David Breckenridge, who serves as chief scientific officer. Both previously held senior leadership positions at Actio Biosciences.

The company develops small-molecule medicines using insights from human genetics, drug discovery and data science. Its research focuses on identifying genetic mechanisms responsible for rare diseases and developing targeted therapies that may also have applications in more common conditions.

Setara’s lead programme is STAR-0871, formerly known as ABS-0871, an investigational oral small-molecule inhibitor of the TRPV4 ion channel. The drug is being developed for Charcot-Marie-Tooth disease type 2C (CMT2C), a rare inherited neuromuscular disorder associated with mutations in the TRPV4 gene, and for overactive bladder.

The company has completed the healthy-volunteer portion of a Phase 1 clinical trial evaluating STAR-0871. It plans to initiate a Phase 1b study, named THERON, in patients with CMT2C in 2027, alongside a separate Phase 2a study investigating the treatment in patients with overactive bladder.

STAR-0871 has received Rare Pediatric Disease, Orphan Drug and Fast Track designations from the US Food and Drug Administration for its rare disease development programme. These designations support aspects of drug development but do not constitute regulatory approval.

Beyond STAR-0871, Setara is developing earlier-stage discovery programmes targeting genetic epilepsies and exploring additional therapeutic indications, including migraine.

The Series A financing will support the company’s planned clinical studies and further development of its genetics-based drug discovery pipeline.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share